文献速递糖尿病

资源有限地区1型糖尿病儿童与年轻成人中人体胰岛素与类似物胰岛素的比较(HumAn-1):多中心、开放标签、随机对照试验

Human versus analogue insulin for children and young adults with type 1 diabetes in low-resource settings (HumAn-1): a multicentre, open-label, randomised controlled trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2026-07-06

HumAn-1试验在孟加拉国和坦桑尼亚的7-25岁1型糖尿病患者中比较甘精胰岛素与常规护理(中效人体胰岛素或预混70/30)对严重低血糖风险及目标范围内时间的影响。6个月时,两组极低血糖范围内时间和目标范围内时间均无显著差异。

要点

  • 在资源有限地区,甘精胰岛素与人体中效胰岛素相比未显著改善极低血糖范围内时间。
  • 甘精胰岛素与常规护理在目标范围内时间上也无显著差异。
  • 两组严重不良事件均较少,甘精胰岛素组5例(3%)发生6次SAE,常规护理组13例(6%)发生14次SAE。

核心结论

  • 在资源有限地区,1型糖尿病儿童和年轻成人使用甘精胰岛素与常规护理相比,6个月时极低血糖范围内时间和目标范围内时间均无显著差异。

研究设计与样本

  • HumAn-1为多中心、开放标签、平行组随机对照试验,在孟加拉国1个中心和坦桑尼亚2个中心进行。
  • 共纳入400例7-25岁临床诊断1型糖尿病患者,按1:1随机分配至甘精胰岛素组(n=199)或常规护理组(n=201),按中心分层。

主要发现

  • 甘精胰岛素组5例(3%)共发生6次严重不良事件,常规护理组13例(6%)共发生14次严重不良事件。

临床怎么用

  • 在资源有限地区,对于1型糖尿病儿童和年轻成人,甘精胰岛素与人体中效胰岛素在血糖控制关键指标上无显著差异,临床选择可综合考虑可及性和成本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Human insulins including intermediate-acting human insulin (ie, isophane insulin) remain widely used for children and young people with type 1 diabetes, especially in low-resource settings. We aimed to assess whether insulin glargine reduces the risk of serious hypoglycaemia or improves time in range when compared against human isophane insulin among children and young people with type 1 diabetes in low-income and middle-income countries. METHODS: HumAn-1 was a randomised, open label, parallel-group trial conducted at one site in Bangladesh and two sites in Tanzania. Participants aged 7-25 years with a clinical diagnosis of type 1 diabetes were randomly assigned (1:1) to receive insulin glargine (Basaglar, Eli Lilly, Indianapolis, IN, USA) or to continue usual care (ie, isophane insulin or premixed 70/30) for basal insulin coverage. Insulin glargine was administered subcutaneously, usually before bedtime. Isophane insulin or premixed 70/30 was administered once or twice per day, at the discretion of the treating clinician. Doses varied by participant. Randomisation was performed centrally and stratified by site. The coprimary outcomes, measured using blinded continuous glucose monitors at 6 months, were time in very low range (<3 mmol/L or 54 mg/dL) and time in target range (3·9 mmol/L to 10·0 mmol/L or 70 mg/dL to 180 mg/dL). The primary analysis was done for the overall intention-to-treat (ITT) population. The safety population included all participants who received at least one dose of study treatment and was analysed according to the treatment actually received. In this study, all participants received at least one dose of their randomly assigned intervention (ie, the ITT population is the same as the safety population). This trial is registered with ClinicalTrials.gov (NCT05614089). FINDINGS: Between March 1 and Dec 19, 2023, we assessed 426 children and young people for eligibility. Of these, 400 (94%) were randomly assigned to receive either glargine (n=199) or usual care (n=201). At 6 months, the mean time in very low range was 3·6% (SD 5·6) in the glargine group and 3·4% (4·3) in the usual care group. After adjustment for prespecified baseline covariates, the adjusted mean difference was 0·22% (97·5% CI -0·83 to 1·27, p=0·63). The mean time in target range was 40·5% (SD 18·4) for glargine and 38·1% (18·1) for usual care. The adjusted mean difference was 0·55% (97·5% CI -2·78 to 3·89, p=0·71). Serious adverse events (SAEs) were uncommon, with a total of six SAEs among five (3%) of 199 participants in the glargine group and 14 SAEs among 13 (6%) of 201 participants in the usual care group. INTERPRETATION: At 6 months, children and young people with type 1 diabetes living in low-resource settings randomly assigned to glargine had no evidence of effects on time in very low range and time in target range compared with those assigned to usual care. FUNDING: The Leona M. and Harry B. Helmsley Charitable Trust.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Luo J, Kehlenbrink S, Chang CH, et al. Human versus analogue insulin for children and young adults with type 1 diabetes in low-resource settings (HumAn-1): a multicentre, open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2026. PMID: 42409045. doi:10.1016/S2213-8587(26)00097-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。